CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Large Drop in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 326,576 shares, a drop of 37.2% from the July 15th total of 519,924 shares. Based on an average daily trading volume, of 497,187 shares, the short-interest ratio is presently 0.7 days. Approximately 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

CSLLY has been the topic of several recent research reports. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.

CSL Stock Performance

OTCMKTS CSLLY opened at $28.10 on Wednesday. The business’s 50 day moving average is $21.34 and its two-hundred day moving average is $27.26. CSL has a 12-month low of $16.01 and a 12-month high of $37.90. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.